- Home
- AKA vs ABOS Comparison
AKA vs ABOS Comparison
Compare AKA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | ABOS |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.6M | 113.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AKA | ABOS |
|---|---|---|
| Price | $11.78 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $24.33 | $7.67 |
| AVG Volume (30 Days) | 4.1K | ★ 209.0K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $595,281,000.00 | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $4.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.44 | N/A |
| 52 Week Low | $7.00 | $0.86 |
| 52 Week High | $19.90 | $2.46 |
Technical Indicators
Market Signals| Indicator | AKA | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 36.91 |
| Support Level | $10.84 | $1.90 |
| Resistance Level | $12.12 | $2.39 |
| Average True Range (ATR) | 0.52 | 0.15 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 81.82 | 7.64 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.